# A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Brexpiprazole for Extended-Release Injection in Subjects With Schizophrenia

> **NCT07742280** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Bostal Drug Delivery Co., Ltd** · enrollment: 16 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Brexpiprazole for ER injection, 45 mg
- **DRUG:** Brexpiprazole for ER injection, 100 mg

## Key facts

- **NCT ID:** NCT07742280
- **Lead sponsor:** Bostal Drug Delivery Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2027-08
- **Final completion:** 2027-12
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07742280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07742280, "A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Brexpiprazole for Extended-Release Injection in Subjects With Schizophrenia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07742280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*